StockData
Regentis Biomaterials Ltd. logo

Regentis Biomaterials Ltd. (RGNT) stock

RGNTNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Feb 24, 2026Score 1/30
$1.14−0.08 (-6.56%)

Close on Nov 18, 2026Market cap $5.90MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
$5.90M
P/E ratio
–
Price to sales
–
Price to book
0.77
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$13.65M
EPS, diluted
-$24.16

Trading

Previous close
$1.22
Open
$1.22
Day's range
$1.14 – $1.22
Volume
9,157
Average volume (20 days)
46,874
52-week range
$1.14 – $15.50
RSI (14 days)
33.8
Volatility (1 year)
559.3%
Relative volume
0.14×

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.

PeriodRGNTS&P 500DifferenceRGNT per yearS&P 500 per year
1 month-23.5%-4.3%−19.2 pts
3 months-42.7%-4.6%−38.1 pts
Year to date-83.1%+7.9%−91.0 pts
1 year+11300.0%+11.8%+11288.2 pts
3 years+11300.0%+68.0%+11232.0 pts+384.9%+18.9%
5 years+11300.0%+66.2%+11233.8 pts+157.9%+10.7%
10 years+11300.0%+291.3%+11008.7 pts+60.6%+14.6%

Four years at a glance

Fiscal years 2022 to 2025, USD

Operating income

-$6.97M-847.6% YoY

Net income

-$13.65M-384.3% YoY

EPS, diluted

-$24.16-1504.7% YoY
Reported period

Press releases

Releases Regentis Biomaterials filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Regentis Biomaterials

Orthopedic, Prosthetic & Surgical Appliances & Supplies

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions designed to restore health and improve patient quality of life. The company focuses on orthopedic therapies utilizing its Gelrin platform, which employs degradable hydrogel implants to regenerate damaged or diseased cartilage. Its primary product candidate is GelrinC, an acellular, off-the-shelf hydrogel cured into an implant to treat painful articular knee cartilage injuries. GelrinC serves human patients suffering from knee cartilage damage and targets European markets through planned partnerships.

Company profile, executives and history

Regentis Biomaterials stock: common questions

What is Regentis Biomaterials's stock price?

RGNT closed at $1.14 on Nov 18, 2026, down 6.56% on the day. Over the past 52 weeks it traded between $1.14 and $15.50.

What is Regentis Biomaterials's market cap?

Regentis Biomaterials was worth $5.90M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.

What is RGNT's P/E ratio?

Regentis Biomaterials lost money over fiscal 2025 (diluted EPS -$24.16), so it has no meaningful P/E ratio.

Does Regentis Biomaterials pay a dividend?

No. Regentis Biomaterials has not paid a cash dividend over the last twelve months.

How has RGNT stock performed over the past year?

Including dividends, RGNT returned +11300.0% over the past year, against +11.8% for the S&P 500.

How many RGNT shares are sold short?

0M shares were sold short at the latest FINRA report, 0.19% of the float, or 1.0 days of average trading volume.

Who are Regentis Biomaterials's competitors?

Companies most similar to Regentis Biomaterials by business, industry and size include OPHI, SNN, ENOV, SMTI, AVR.

See a number that looks wrong?